Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis
Open Access
Abstract
Objective To compare the clinical efficacy and bioequivalence of generic immunosuppressive drugs in patients with solid organ transplants. Design Systematic review and meta-analysis of all studies comparing generic with innovator immunosuppressive drugs. Data sources Medline and Embase from 1980 to September 2014. Review methods A literature search was performed for all studies comparing a generic to an innovator immunosuppressive drug in solid organ transplantation. Two reviewers independently extracted data and assessed quality of studies. Meta-analyses of prespecified outcomes were performed when deemed appropriate. Outcomes included patient survival, allograft survival, acute rejection, adverse events and bioequivalence. Results 1679 citations were screened, of which 50 studies met eligibility criteria (17 randomized trials, 15 non-randomized interventional studies, and 18 observational studies). Generics were compared with Neoral (cyclosporine) (32 studies), Prograf (tacrolimus) (12 studies), and Cellcept (mycophenolate mofetil) (six studies). Pooled analysis of randomized controlled trials in patients with kidney transplants that reported bioequivalence criteria showed that Neoral (two studies) and Prograf (three studies) were not bioequivalent with generic preparations according to criteria of the European Medicines Agency. The single Cellcept trial also did not meet bioequivalence. Acute rejection was rare but did not differ between groups. For Neoral, the pooled Peto odds ratio was 1.23 (95% confidence interval 0.64 to 2.36) for kidney randomized controlled trials and 0.66 (0.40 to 1.08) for observational studies. For kidney observational studies, the pooled Peto odds ratios were 0.98 (0.37 to 2.60) for Prograf and 0.49 (0.09 to 2.56) for Cellcept. Meta-analyses for non-renal solid organ transplants were not performed because of a lack of data.There were insufficient data reported on patient or graft survival. Pooling of results was limited by inconsistent study methods and reporting of outcomes. Many studies did not report standard criteria used to determine bioequivalence. While rates of acute rejection seemed similar and were relatively rare, few studies were designed to properly compare clinical outcomes. Most studies had short follow-up times and included stable patients without a history of rejection. Conclusions High quality data showing bioequivalence and clinical efficacy of generic immunosuppressive drugs in patients with transplants are lacking. Given the serious consequences of rejection and allograft failure, well designed studies on bioequivalence and safety of generic immunosuppression in transplant recipients are needed.Keywords
This publication has 77 references indexed in Scilit:
- Conversion to generic cyclosporine A in stable chronic patients after heart transplantationDrug Design, Development and Therapy, 2013
- A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant RecipientsAmerican Journal of Transplantation, 2012
- Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipientsTransplant International, 2012
- Safety and Efficacy of Generic Cyclosporine Arpimune in Filipino Low-Risk Primary Kidney Transplant RecipientsTransplantation Proceedings, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trialKidney International, 2010
- Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysisKidney International, 2010
- Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular DiseaseJAMA, 2008
- Do we have the same clinical results with Neoral®and Equoral®treatment in kidney transplant recipients? A pilot studyTransplant International, 2008
- The Utility of the Population Approach Applied to Bioequivalence in PatientsTherapeutic Drug Monitoring, 2005